1. Home
  2. SNAL vs BOLD Comparison

SNAL vs BOLD Comparison

Compare SNAL & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Snail Inc.

SNAL

Snail Inc.

N/A

Current Price

$0.81

Market Cap

40.1M

Sector

Technology

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$1.47

Market Cap

36.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SNAL
BOLD
Founded
2000
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
40.1M
36.5M
IPO Year
2022
2024

Fundamental Metrics

Financial Performance
Metric
SNAL
BOLD
Price
$0.81
$1.47
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
10.8M
129.5K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
120.00
32.47
EPS
N/A
N/A
Revenue
$81,225,622.00
N/A
Revenue This Year
$15.53
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.96
52 Week High
$2.16
$1.68

Technical Indicators

Market Signals
Indicator
SNAL
BOLD
Relative Strength Index (RSI) 48.54 53.01
Support Level $0.62 $1.40
Resistance Level $0.98 $1.53
Average True Range (ATR) 0.15 0.06
MACD -0.03 -0.01
Stochastic Oscillator 7.40 51.43

Price Performance

Historical Comparison
SNAL
BOLD

About SNAL Snail Inc.

Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: